Splicing of exons 2 and 3 of α-tropomyosin
(TM) involves mutually exclusive selection of either exon
3, which occurs in most cells, or of exon 2 in smooth muscle
(SM) cells. The SM-specific selection of exon 2 results
from the inhibition of exon 3. At least two essential cis-acting
elements are required for exon 3 inhibition, the upstream
and downstream regulatory elements (URE and DRE). These
elements are essential for repression of TM exon 3 in SM
cells, and also mediate a low level of repression of exon
3 in an in vitro 5′ splice site competition assay
in HeLa extracts. Here, we show that the DRE consists of
at least two discrete components, a short region containing
a number of UGC motifs, and an essential pyrimidine-rich
tract (DY). We show that the specific sequence of the DY
element is important and that DY is able to bind to factors
in HeLa nuclear extracts that mediate a low background
level of exon 3 skipping. Deletion of a sequence within
DY identified as an optimal binding site for PTB impairs
(1) regulation of splicing in vivo, (2) skipping of exon
3 in an in vitro 5′ splice site competition, (3)
the ability of DY competitors to affect the 5′ splice
site competition in vitro, and (4) binding of PTB to DY.
Addition of recombinant PTB to in vitro splicing reactions
is able to partially reverse the effects of the DY competitor
RNA. The data are consistent with a model for regulation
of TM splicing that involves the participation of both
tissue-specific and general inhibitory factors and in which
PTB plays a role in repressing both splice sites of exon
3.